A phase I study of tenofovir disoproxil fumarate (PMPA [phosphonomethoxypropyladenine]prodrug), a novel nucleotide analog reverse transcriptase inhibitor in children with HIV infection

Trial Profile

A phase I study of tenofovir disoproxil fumarate (PMPA [phosphonomethoxypropyladenine]prodrug), a novel nucleotide analog reverse transcriptase inhibitor in children with HIV infection

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2007

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Antiretrovirals
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top